SEP Acquisition Corp. (SEPA) Shareholders Approve SANUWAVE Deal
by Marlena Haddad on 2024-01-30 at 4:46pm

SEP Acquisition Corp. (NASDAQ:SEPA) announced this afternoon that its shareholders approved its combination with wound care firm SANUWAVE (OTC:SNWV) during a special meeting on January 29.

At the meeting, holders of 5,146,501 shares of SEPA’s common stock were present, representing 89.46% of the company’s common stock outstanding. The deal was overwhelmingly approved as holders of 5,137,623 shares voted in favor of the deal, while holders of 3,778 shares pushed back against it.

In connection with the vote, stockholders holding 495,067 shares of Class A common stock opted to redeem their shares of Class A common stock. Including prior votes, SEPA stockholders have redeemed an aggregate of 95.1% of the SPAC’s trust thus far, leaving it with approximately $8.5 million and 809,192 shares remaining.

The parties did not provide a timeline for the closing of the deal, but the combined company is expected to trade on the Nasdaq under the symbol “SNWV” once completed.

SEP announced its $127 million deal with SANUWAVE in August 2023. Eden Prairie, Minnesota-based SANUWAVE has commercialized its FDA-approved UltraMist medical device, which accelerates healing and reduces inflammation by delivering a pain-free mist of medicines to the effected area.

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved